PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Update

PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) was the recipient of a large decrease in short interest during the month of May. As of May 15th, there was short interest totaling 8,275 shares, a decrease of 66.3% from the April 30th total of 24,521 shares. Based on an average daily trading volume, of 23,494 shares, the short-interest ratio is presently 0.4 days. Approximately 0.0% of the shares of the company are short sold.

Institutional Trading of PureTech Health

An institutional investor recently raised its position in PureTech Health stock. Pentwater Capital Management LP lifted its position in shares of PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) by 50.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 75,000 shares of the company’s stock after buying an additional 25,000 shares during the period. Pentwater Capital Management LP owned about 0.31% of PureTech Health worth $1,388,000 as of its most recent SEC filing. Institutional investors and hedge funds own 0.04% of the company’s stock.

PureTech Health Stock Performance

PRTC remained flat at $17.42 during trading on Monday. The firm has a 50 day moving average price of $16.93 and a 200 day moving average price of $17.21. PureTech Health has a 12-month low of $14.50 and a 12-month high of $19.92.

PureTech Health (NASDAQ:PRTC) last issued its quarterly earnings data on Friday, April 10th. The company reported ($1.35) earnings per share (EPS) for the quarter. The company had revenue of $1.40 million during the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings cut PureTech Health from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 18th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

PureTech Health Company Profile

PureTech Health (NASDAQ: PRTC) is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.

PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies.